TENX

Summary

Sell TENX, that is Tenax Therapeutics, Inc., at ~1.93 mid-range. Exit existing longs into strength toward 2.00-2.05 VWMA/10-day EMA confluence where 9-17M share liquidity has printed, do not dump full size on thin 0.96M unfinished intraday print; avoid new longs. Position sizing for TENX, that is Tenax Therapeutics, Inc.: flat cash, no short, no naked premium. Key risk levels for TENX, that is Tenax Therapeutics, Inc.: resistance 2.00-2.05 then 2.27 upper Bollinger, support 1.57 lower Bollinger (-18%) then 1.31 crash low (-32%), ATR 0.52 (27% of price) so half-ATR 0.25-0.30 dictates tiny size only. Invalidation: break and hold above 2.27 on expanding volume >9M. Confirmation: daily settlement below 1.57. Time horizon: 5 trading days for alpha vs SPY; remain in cash awaiting filed FDA minutes plus defined trial design plus priced financing before any reconsideration of TENX, that is Tenax Therapeutics, Inc.

The case

Thesis for TENX, that is Tenax Therapeutics, Inc., is Sell as exit/avoid, not as aggressive short, synthesizing all three risk views and the Research Manager plan.

Technicals for TENX, that is Tenax Therapeutics, Inc.: 1.93 intraday Sep 11 (open 1.99 high 2.00 low 1.91 partial 0.967M) sits below 10-day EMA 2.05 and VWMA 2.00, on Bollinger middle 1.92 inside 1.57-2.27 container sensible only since Sep 4. MACD -1.72 improved from -3.57 trough with histogram +0.46 but still deeply negative, RSI 27 pinned under 30 for a month faded from 28.1 on strong day, ATR compressed 1.73 mid-Aug to 0.52. Effort vs result is bearish: Sep 9 push 9.17M shares to 2.13 briefly over EMA ~2.10 failed to 1.95 then 1.93 on <1M, prior supply spikes 17.2M Aug 31 and 14M Sep 3 closed weak vs capitulation 65.5M/32.9M bars, with massive overhead trapped 10-19 and contaminated 50-day 9.11/200-day 11.80.

Fundamentals for TENX, that is Tenax Therapeutics, Inc.: 118M cash vs 72M market cap zero long-term debt current ratio ~15 price/book 0.84 vs book 2.28 looks like floor but is current assets only with zero non-current assets, zero revenue, R&D more than doubled to 12.85M, burn 14.15M, opex ~18.7M vs interest ~1M, stock comp 3.3M real cost, shares 4.1M to 26.5M (+539%) diluted avg 50.8M APIC +75M deficit 400M. Cash held flat only via 30.5M Q1 +13.3M Q2 financing, so 8-10 quarters flat-burn runway is meaningless if second Phase 3 accelerates burn and must be funded via dilution at 1.93 lows.

Event for TENX, that is Tenax Therapeutics, Inc.: LEVEL missed primary in 241 PH-HFpEF, leaving only 26.3m prespecified subgroup with no p-values, safety, FDA minutes, design, timeline or funding; Sep 9 strategy update disclosed no detail with bearish headline alongside, no fresh headlines Sep 10-11, Cantor is pitch not validation, Adar1 1.6M buy same day is 1.3% of cash sentiment cover not funding, analyst target 12.55 is pre-crash anchor.

Sentiment/flow for TENX, that is Tenax Therapeutics, Inc.: 82 confidence bullish 18-to-1 social sentiment channels on $2 breakout call OI 8x puts yet 190k social discussion forums eyes could not lift through 2.00-2.05, bulls citing manipulation/stalled price, median IV 535% with only 329 calls vs 193 puts illiquid crush risk, macro Fear 34.2 with no healthcare driver = idiosyncratic crowded long distribution risk.

Debate reconciliation: Aggressive is right supply controls mid-range and downside is fast 18% to 1.57 and 32%+ to 1.31 in 1-2 ATR moves, and crowded unanimity + IV is fuel for fade. Conservative is right to reject reload short/premium timing due to oversold + positive histogram + halt/gap/squeeze + unfinished thin print slippage, demanding flat no short no auto-reload until filed FDA minutes + design + priced financing. Neutral is right volatility compression is basing not waterfall (EMA decline flattened to cents/day, VWMA 1.96 to 2.00 uptick) and cash buys time not imminent forced event, but wrong to retain stub/chase diversifier when reclaim just failed and financing gap looms. Net: direction Sell, discipline Conservative, execution Neutral (scale exits to 2.00-2.05 liquidity).

Past reflections: No prior resolved TENX, that is Tenax Therapeutics, Inc., analyses, no calibration. Cross-ticker require-confirmed-breakdown-volume (NOK Sell +2.7%/+3.0% 1d, NOK Underweight, AMRC Sell) warns outright Sell-short when coiled without confirmed close below support on expanding volume fails; we respect it by exiting/avoiding TENX, that is Tenax Therapeutics, Inc., with no short, no premium sale, no auto-reload on 2.27 or 1.57. wait-for-resistance-settlement requires expanding volume through 2.00-2.05 then 2.27 before any add; buying-overbought-extension warns against chasing subgroup headlines. Paying 1.93 mid-range for a failed-primary story needing FDA alignment + new powered trial + tens of millions dilution, none verified, vs clean downside to 1.57/1.31 capped by 2.00-2.27 supply, is negatively skewed.

What would weaken it

• Dilution at lows to fund second powered trial
• Oversold halt/gap/squeeze on thin prints
• Illiquid options IV crush at 535% median